Chair HMA Task Force; Executive Director, Medicines Evaluation Board (MEB)
NM
Director of Policy, Genetic Alliance UK
Nick Meade leads the policy work of Genetic Alliance UK. The organisation works on behalf of more than 230 patient organisation member groups, aiming to improve outcomes for everyone affected by genetic, rare and undiagnosed conditions through evidence-based influencing and campaigning...
Read More → 
Chair, EMA Management Board, Head, Austrian Medicines and Medical Devices Agency
Christa Wirthumer-Hoche studied biochemistry TU Vienna, doctoral thesis at Medical Physiology. Starting at the AT Nat. Inst. for Quality Control of Drugs - quality assessment, Head of Regulatory Affairs in the Ministry of Health, Now Head of the Austrian Medicines and Medical Devices...
Read More →
Head of Scientific Committees Regulatory Science Strategy, European Medicines Agency (EMA)
He is the Head of Scientific Committees Regulatory Science Strategy Division (SciRS). He is responsible for providing leadership in the Agency in the areas of Scientific Committees Coordination and Regulatory Science Strategy in support of delivering the EMRN 2020 Strategy. He chairs...
Read More →
Chief Executive, Health Products Regulatory Authority (HPRA)
Ms Nolan joined the HPRA in 2001 and since that time has held a number of different roles at senior level within the organisation across a range of areas including inspection and authorisation of human medicines, medical devices, cosmetics and controlled substances. Prior to assuming...
Read More →KD
CMDh member (EU-representative)/Policy adviser, Medicines Evaluation Board
Her current position (since 2009) is CMDh member (EU-representative)/Policy adviser of the department Policy, Governance and Regulatory Affairs. Since May 2009 she is acting as Member and official representative in the CMDh on behalf of the MEB. She is member of several working parties...
Read More → AT
Director Global Regulatory Policy, MSD
Aimad Torqui is Director of Global Regulatory Policy at MSD. Previous employment includes Medicines Evaluation Board and Novartis Vaccines. He has worked with governments, regulators, trade bodies and other external stakeholders to shape robust science-based regulatory policy.
